SCHEMBL4941606

SCHEMBL4941606

CN1CCc2ccccc2[C@H](N)C1=O.Cc1ccc(C(=O)O[C@](C(=O)O)(C(=O)c2ccc(C)cc2)[C@@H](O)C(=O)O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XIAP P98170 1/20 0.39
OPRM1 P35372 6/20 0.37
OPRK1 P41145 5/20 0.37
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PKM P14618 1/20 0.33
APEX1 P27695 1/20 0.33
CYP2C19 P33261 1/20 0.33
BLM P54132 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4941581 0.82 OPRM1 (0.44) XIAPOPRM1OPRK1PSEN1PSEN2
SCHEMBL4941582 0.81 XIAP (0.44) XIAPOPRM1OPRK1PSEN1PSEN2
SCHEMBL2986285 0.76 TDP1 (0.42) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL88252 0.76 TDP1 (0.42) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL27955132 0.76 TDP1 (0.42) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL6532888 0.76 TDP1 (0.42) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL5461407 0.76 TDP1 (0.42) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL72683 0.76 TDP1 (0.42) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL72172 0.76 TDP1 (0.42) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL7355024 0.75 TDP1 (0.41) NPC1RAB9AKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7468365-B2 Lactam compound ELI LILLY AND COMPANY (US) 2008-12-23 US disclosed
EP-1345955-B1 LACTAM DIPEPTIDE AND ITS USE IN INHIBITING BETA-AMYLOID PEPTIDE RELEASE LILLY CO ELI (US) 2008-08-20 EP disclosed
US-20070299053-A1 Lactam compound ELI LILLY AND COMPANY 2007-12-27 US disclosed
EP-1353910-B1 LACTAM COMPOUND LILLY CO ELI (US) 2007-05-23 EP disclosed
EP-1341531-B1 LACTAM COMPOUND TO INHIBIT BETA-AMYLOID PEPTIDE RELEASE OR SYNTHESIS LILLY CO ELI (US) 2007-01-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299053-A1 Lactam compound AAAS, ORMDL3, NAALAD2 XIAP 3446/4885OPRM1 2251/4885OPRK1 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.